Forbes March 26, 2024
Alex Knapp

The pharmaceutical giant’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials.

Nearly 40,000 Americans are known to suffer from pulmonary arterial hypertension (PAH), a disease that causes the blood vessels in their lungs to progressively shrink, increasing both blood pressure and the risk of heart failure. Around 500 to 1,000 new cases are diagnosed every year, with the average patient only surviving about five to seven years after being diagnosed. The vast majority of people with this disease are women, and they are disproportionately Black or Hispanic.

On Tuesday, the Food and Drug Administration approved a new drug to treat this disease called sotatercept which was developed and being...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA Approves First Biosimilar of Xolair
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article